BioCentury | Apr 15, 2021
Deals

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 13, 2021
Deals

Sanofi joins in vivo cell engineering wave, snapping up stealthy Fred Hutch mRNA delivery spinout

Acquired by Sanofi before making its official debut, Tidal is the latest example of a vector-focused company enabling democratization of immune cell therapies via in vivo engineering.  Shareholders of the Fred Hutchinson Cancer Research Center...
BioCentury | Apr 9, 2021
Deals

April 8 Quick Takes: Hologic buying Mobidiag for nearly $800M; plus Biogen-Bio-Thera, Dicerna royalty sale, a SPAC for LumiraDx, Cidara-Janssen and Chi-Med’s $100M

Women’s health company Hologic Inc. (NASDAQ:HOLX) is acquiring Mobidiag Ltd., a Finnish-French maker of molecular diagnostics and instruments, for about $795 million, including $741 in cash and the assumption of net debt of about $81...
BioCentury | Apr 8, 2021
Finance

With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight

Cross-border firm Remiges Ventures will deploy its $95 million second fund to launch start-ups out of Japanese academia and invest in syndicated series A rounds, with a newly launched incubator to help...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...
BioCentury | Mar 31, 2021
Finance

March 31 Quick Takes: Muted reception for Achilles in market debut; plus BridgeBio-Helsinn, Scribe, Outpace, OnQuality, AffaMed, Treos

Achilles Therapeutics Inc. (NASDAQ:ACHL) briefly traded above its $18 IPO price before ceding ground in its first day of trading, settling to $16.55 in trading Wednesday. The clinical T cell therapeutics developer raised $175.5 million through...
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

Cross-border company AffaMed now has more than $170 million in series B funding and the backing of Lake Bleu Capital to pair with its hiring of one of China’s most prominent dealmakers, Ji Li,...
BioCentury | Mar 27, 2021
Product Development

What it will take to meet CEPI’s 100-day vaccine goal for the next pandemic

As CEPI looks to prepare for the next pandemic, it has set a lofty goal to reduce to 100 days the time from sequencing the pathogen to a regulatory submission of a vaccine. But meeting...
BioCentury | Mar 25, 2021
Emerging Company Profile

Asher Bio: aiming cytokine therapies at specific immune cells

Asher Bio emerged from stealth Tuesday with a $55 million series A led by Third Rock and a platform to improve the safety and efficacy of cytokine therapies for cancer.  Boxer Capital, Invus and seed...
BioCentury | Mar 19, 2021
Product Development

Pandemic response ushers in new era of biopharma data sharing: Guest Commentary

Years before the novel coronavirus began cutting its lethal course across nearly every continent on earth, scientists and senior executives at leading biopharmaceutical companies were discussing ways of accelerating the design, efficiency and pace of...
Items per page:
1 - 10 of 5540